RE:Compare Good report, I like the way these guys are thinking...
"Overall, Valens has a clear and distinct advantage over Medipharm based on many share price performance indicators examined. While there are many other metrics and fundamentals that drive overall growth, these will be examined by Harvest Moon Research in Part 2 and 3 of this extended report. These performance indicators exemplified in this report create the foundation needed for a profitable long-term investment, while extraction capacity and customer satisfaction are considered complementary.
What remains to be undisputed is that the bare bones of Valens are much stronger than that of any competitors in it’s class. It could be even argued further that MediPharm isn’t even second best in its class anymore, where that distinction could be easily given to Neptune Wellness with next quarters revenue estimates ranging from $28m to $29.2m. However, there is no doubt in investors minds when it comes to cannabis that Valens will remain to be the leader of the pack for years to come.
Advantage Valens"